GlaxoSmithKline Pharmaceuticals Limited — Updates, 14-02-2025: Press Release

GlaxoSmithKline Pharmaceuticals Ltd (GSK) reported a strong third-quarter performance with an 18% rise in revenue from operations, totaling INR 946 crores, and a Profit After Tax (PAT) of INR 229 crores. The growth was driven by solid performances in key product portfolios, particularly the general medicines segment with flagship brands like Augmentin and Ceftum gaining market share. Additionally, GSK's innovative Respiratory portfolio, featuring Nucala and Trelegy, experienced notable growth, expanding patient access across India. In the vaccine segment, GSK maintained its leadership in the self-pay market for pediatric vaccines and saw momentum in adult vaccines, primarily with Shingrix. The Managing Director emphasized the company's focus on core brands and digital transformation, aiming to enhance market presence and ensure broader access to healthcare solutions. This robust performance positions GSK favorably for continued growth in the competitive healthcare landscape. Investors should maintain a positive outlook as GSK capitalizes on its strengths and market opportunities.